Business
PDMR Dealing and Total Voting Rights
PDMR Dealing and Total Voting Rights.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n \n \n 16 September 2022\n \n \n \n \n \n \n Futura Medical plc\n \n \n \n \n (\"Futura\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Exercise of Options, PDMR Dealing and Total Voting Rights\n \n \n \n \n \n \n Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces that it has received notice to exercise options from James Barder, CEO, to exercise 500,000 options over ordinary shares of 0.2 pence in the Company (\"Ordinary Shares\").\n \n \n \n \n \n James Barder has exercised options over 250,000 Ordinary Shares with an exercise price of 30 pence and options over 250,000 Ordinary Shares with an exercise price of 7.5 pence. In order to satisfy the exercise price of these options, 250,000 Ordinary Shares have been sold, with the remaining 250,000 Ordinary Shares retained. In addition, James and his spouse, Charlotte Barder have gifted 20,000 Ordinary Shares to a family member as part of inheritance and tax planning.\n \n \n \n \n \n Following these transactions\n James Barder's interests in Ordinary Shares has increased to 1,440,972 Ordinary Shares, representing approximately 0.5% of the Company's issued share capital.\n \n \n \n \n \n \n Total Voting Rights\n \n \n \n \n \n \n Following the issue of 500,000 Ordinary Shares under the Company's existing block listings to satisfy the exercise of options, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is\n 287,650,971\n Ordinary Shares.\n \n \n Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is\n 287,650,971\n and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\n \n \n \n \n \n \n -ENDS-\n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n Futura Medical plc\n \n \n \n James Barder, Chief Executive\n \n \n Angela Hildreth, Fin...